Cure SCA

Charity dedicated to help cure Spino-Cellebellar Ataxia 3

[Cure SCA @CureSCA3]

Many thanks @AtaxiaCentreUCL .We are very proud to have part-funded this project and delighted that this ground breaking research yielded exciting results that paves the way future treatments. Our sincere thanks to Dr.Hector Garcia-Morena & Prof.Giunti and all other collaborators

[Movement Disorders Clinical Practice @MDCP_Journal]

Difficulties of Access to Diagnostic Methods and Therapies in Movement Disorders: A Call to Action @movedisorder @kailashbhatia @mmerello https://t.co/M8BZdYRI2F

[C. Roy Lin, MD, MPH, FAAN @RoyCLinMD]

Will you consider screening fatigue for people with #cerebellar #ataxia?

Our new study @MDCP_Journal reveals #fatigue's significant impact in SCAs, affecting over half of SCA3 and also common in SCA 1, 2, 6.

The data also suggest that fatigue is more closely related to non-motor (ie, depression) than motor symptoms (ie, #ataxia severity) in SCAs.

https://t.co/GiNYxCKWX2

[National Ataxia Foundation @NAF_Ataxia]

Biohaven announced that they have continued to have constructive dialogue with the FDA regarding its SCA development program and potential future data analyses to address regulatory concerns in the previously issued refuse-to-file decision on its NDA application for SCA3. (1/2)

[Cure SCA @CureSCA3]

@OTSociety #SCA3 NEXT.

[Oligonucleotide Therapeutics Society @OTSociety]

The First FDA Approval for a GalNAc-conjugated ASO ⬇️

https://t.co/uIoTRUAkry

#ots #oligotherapeutics #oligonucleotide #biotech #science #research #currentscience #attramyloidiosis #fda #fdaapproved #GalNAc #amlyoidosis #wainua #amyloidosistreatment #hATTR #pharmaceuticals

[SCAsource @SCAsource]

La medición de los niveles de las proteínas de poliQ ATXN3 en el líquido cefalorraquídeo y plasma distingue a pacientes SCA3 de los individuos no afectados https://t.co/HnSyxk3CcQ

[Laurens Bosman @LWJBosman]

Following mouse models for #Purkinje cell degeneration over time, we noticed that #cerebellar #ataxia does not develop gradually, but involves specific phases. The sequence in which gaiting parameters deteriorate depends on the underlying pathology.
https://t.co/4gwY0B2Tp9

[Jonasz J. Weber @JonaszWeber]

Our paper on a novel KPNB1/CLPP-dependent degradation pathway for the Machado-Joseph disease protein ataxin-3 has just gone online! Check out this exciting study published in @SpringerNature’s Cellular & Molecular Life Sciences (CMLS): https://t.co/QhOqbHAsfj

#SCA3 #neuroscience

[AtaxiasARG @AtaxiasARG]

The role if the cerebellum in learning to predict reward: alongside its role in motor learning, the #cerebellum likely operates in concert with the basal ganglia to support reinforcement learning from #reward.
@RoyCLinMD
@KuoMDCerebellum
https://t.co/v3GVhJnl8h

[Ataxia Global Initiative @ataxia_global]

@UNCneurology Ataxia Global Initiative works on facilitation of clinical development of ataxia therapies.

Together for ataxia!

Register for
Ataxia Global Conference on Best Endpoints in Ataxia
https://t.co/JCesqXmz3V

[Ataxia UK @AtaxiaUK]

At the Ataxia UK annual conference, Dr. Shpresa Pula and Dr Paola Giunti will be running a Q&A on Friedreich’s ataxia. Please email your questions in advance to [email protected] with the subject line 'FA Q&A'.

#AtaxiaUK #Ataxia #FA #Conference2023

[Ataxia UK @AtaxiaUK]

📣Tomorrow is International Ataxia Awareness day!

Georg has Friedreich’s ataxia (FA) and has been living with this condition for 8 years. He also believes that late diagnosis could be crucial for patients.

Make a difference: https://t.co/TIFbfOeV8V

#AtaxiaUK #IAAD2023

[National Ataxia Foundation @NAF_Ataxia]

Today is #InternationalAtaxiaAwarenessDay! Share and like this post to create #AtaxiaAwareness. We'll be posting all day so follow along.

[SCAsource @SCAsource]

Advanced Magnetic Resonance Imaging (MRI) detects brain changes before #ataxia symptoms. https://t.co/hrGTtfex8j

[SCAsource @SCAsource]

Using statistics, a meta-analysis synthesizes the findings of multiple similar scientific studies to produce an overall result. https://t.co/3Ks6iwXwC4

[MDS @movedisorder]

Spinocerebellar ataxia type 1 (SCA1) is caused by a polyglutamine expansion in the ataxin-1 protein. A recent study used patient-specific fibroblasts and SCA1 iPSCs to identify relevant disease phenotypes. https://t.co/NUM5YL0xKI

[Cure SCA @CureSCA3]

@hubermanlab @david_j_linden @HopkinsMedicine Are there breathing protocols recommended for cerebellar disorders such as ataxia that could potentially modulate brain functioning?

[CheckRare @CheckRare]

Scott Schobel, MD, chief medical officer at Vico Therapeutics, discussed the latest data testing an antisense therapy to treat Huntington’s disease and spinocerebellar ataxia type 1 #SCA1 and type 3 #SCA3 #checkrare @HDA_tweeting
https://t.co/ra1SbUDw88

[Jonasz J. Weber @JonaszWeber]

Our Frontiers Research Topic on the Role of Posttranslational Modifications in Polyglutamine Diseases came to a conclusion with the publication of our Editorial. Many thanks to the fantastic team of Co-Editors for the collaboration on this project! https://t.co/tXtpZf5mqG

[National Ataxia Foundation @NAF_Ataxia]

@US_FDA recently issued a Refuse to File letter to @Biohaven regarding its New Drug Application (NDA) for troriluzole to treat SCA3. NAF calls on the FDA to apply regulatory flexibility & accept the NDA for troriluzole. Read our full statement: https://t.co/LtHu1MhVM2 (1/3)